Proceedings of the Tenth International Conference of Drug Regulatory Authorities (ICDRA) - Hong Kong, China, 24 - 27 June 2002
(2002; 166 pages) View the PDF document
Table of Contents
View the documentAbbreviations and acronyms used in this report
Open this folder and view contentsOpening ceremony
Open this folder and view contentsHerbal medicines
Open this folder and view contentsKeynote address
Open this folder and view contentsSafety of blood-derived products
Open this folder and view contentsAntimicrobial resistance - new initiatives
Open this folder and view contentsHarmonization I
Open this folder and view contentsHarmonization II
Open this folder and view contentsProtection of trial subjects in clinical trials
Open this folder and view contentsRegulating biotechnology products
Close this folderRegulatory challenges: health sector reform and drug regulatory capacity
View the documentStrengthening regulatory capacity during reform
View the documentThe creation of a trans-Tasman therapeutic products regulatory agency: a case study in cooperation
View the documentThe South African experience
View the documentDrug registration and importation control in Tunisia
View the documentHealth reform and drug regulation in Venezuela
View the documentEconomic regulation of pharmaceuticals in Brazil
View the documentRecommendations
Open this folder and view contentsAccess to drugs and vaccines I
Open this folder and view contentsAccess to drugs and vaccines II
Open this folder and view contentsCounterfeit pharmaceutical products
Open this folder and view contentsHomoeopathy
Open this folder and view contentsSafety monitoring
Open this folder and view contentsE-Commerce
Open this folder and view contentsCurrent topics
Open this folder and view contentsRegulatory challenges of new technologies
View the documentList of participants
View the documentBack cover
 

Health reform and drug regulation in Venezuela

Dr Esperanza Briceño, Venezuela

In order to improve the Health Services in Venezuela, which were previously highly centralized and inefficient, a new health law has been developed. The aims of the reform were to improve surveillance, strengthen the role of the public sector, decentralize operational and enforcement work, and improve access to medicines. It seeks to do this through a unified, decentralized health system, directed by the Ministry of Health, with institutional and legal autonomy and participation from the community sector. Apart from ensuring the safety, efficacy and quality of medicine, the new law requires drug manufacturers and distributors to be competent, health professionals to be highly qualified, and information to be complete and impartial. The new health act makes the work of the regulatory authority transparent and participatory. It has also enabled the setting-up of independent advisory committees for the regulatory authority and gives the authority power to impose sanctions.

Drug regulation is an essential function of the state, and public health interests should prevail over professional or commercial interests. Health authorities should ensure the availability of essential medicines.

to previous section
to next section
 
 
The WHO Essential Medicines and Health Products Information Portal was designed and is maintained by Human Info NGO. Last updated: November 5, 2014